Novel Inhibitors of p53 for Treatment of Neurodegenerative Disorders, Myocardial Infarction and Other Tissue Insults
Description of Invention:
The tumor suppressor protein p53 is a key modulator of stress responses, and activation of p53 precedes apoptosis (programmed cell death) in many cell types. Conditions that stress tissue, such as deposition of amyloid b-peptide, may thus cause tissue degeneration through activation or up-regulation of p53. This invention provides novel inhibitors of p53 and methods of using these inhibitors for the prevention or treatment of the stress related tissue degeneration observed in Alzheimer's disease, myocardial infarction and stroke. In vitro and ex vivo studies demonstrated that p53 inhibition protected nerve cells from toxic insults that otherwise induced programmed cell death. In a rat model of stroke, p53 inhibition produced a 50% reduction in stroke volume.
Inventors:
Nigel H. Greig et al. (NIA)
Patent Status:
DHHS Reference No. E-222-2000/0 --
U.S. Provisional Application No. 60/216,388 filed 06 Jul 2000
International Application No. PCT/US01/21504 filed 06 Jul 2001
U.S. Patent Application No. 10/332,115 filed 03 Jan 2003
Portfolios: Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Alzheimer Central Nervous System -Therapeutics-Neurological Therapeutics-Stroke Central Nervous System -Therapeutics
For Additional Information Please Contact: Norbert J. Pontzer PhD JD
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5502
Email: pontzern@mail.nih.gov
Fax: (301) 402-0220
